David Cressy, DO
Pulmonary Disease · Covington, LANPI 1437108321
Payments from drug & device makers
Across 162 payments — averaging $63.53 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Intuitive Surgical$7K
- Inspire Medical Systems, Inc.$932
- GSK$692
- Sanofi$251
- Boehringer Ingelheim$216
- AstraZeneca$205
- plus $868 from 19 others
What the payments were for
- Travel & lodging$1,66916%
- Food & beverage$2,62225%
- Education$6,00058%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Intuitive Surgical | 11 | $7,126 |
| Inspire Medical Systems, Inc. | 3 | $932 |
| GSK | 76 | $692 |
| Sanofi | 13 | $251 |
| Boehringer Ingelheim | 4 | $216 |
| AstraZeneca | 13 | $205 |
| Johnson & Johnson | 1 | $133 |
| Sunovion Pharmaceuticals Inc. | 8 | $112 |
| Actelion Pharmaceuticals US, Inc. | 5 | $99 |
| Regeneron Healthcare Solutions, Inc. | 5 | $92 |
| Insmed, Inc. | 4 | $71 |
| Viatris Specialty LLC | 2 | $48 |
| Merck | 3 | $46 |
| Grifols USA, LLC | 2 | $46 |
| Genentech USA, Inc. | 2 | $37 |
| ANI Pharmaceuticals, Inc. | 1 | $30 |
| United Therapeutics Corporation | 1 | $23 |
| Tempus AI, Inc | 1 | $22 |
| Paratek Pharmaceuticals, Inc. | 1 | $22 |
| Jazz Pharmaceuticals Inc. | 1 | $21 |
| Mylan Specialty L.p. | 1 | $15 |
| Lilly USA, LLC | 1 | $15 |
| Philips North America LLC | 1 | $12 |
| AbbVie | 1 | $12 |
| Portola Pharmaceuticals, LLC | 1 | $11 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- Da Vinci Surgical System$6,933
- Inspire$911
- Monarch Platform$133
How this compares
$10,291 in reported general payments places this provider in the 65th percentile of 189 pulmonary disease providers in Louisiana.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| OpsumitMacitentan | 35 | $444,000 |
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 416 | $342,865 |
| OfevNintedanib Esylate | 31 | $339,736 |
| Prolastin CAlpha-1-Proteinase Inhibitor | 12 | $138,801 |
| Breo ElliptaFluticasone/Vilanterol | 99 | $47,274 |
| Anoro ElliptaUmeclidinium Brm/Vilanterol Tr | 58 | $32,576 |
| Breztri AerosphereBudesonide/Glycopyr/Formoterol | 50 | $31,278 |
| Stiolto RespimatTiotropium Br/Olodaterol Hcl | 42 | $28,657 |
| Spiriva RespimatTiotropium Bromide | 21 | $18,886 |
| SymbicortBudesonide/Formoterol Fumarate | 65 | $16,368 |
| Advair HfaFluticasone Propion/Salmeterol | 16 | $9,275 |
| Combivent RespimatIpratropium/Albuterol Sulfate | 18 | $8,555 |
| Albuterol Sulfate HfaAlbuterol Sulfate | 222 | $8,082 |
| Fluticasone-SalmeterolFluticasone Propion/Salmeterol | 19 | $4,709 |
| Ventolin HfaAlbuterol Sulfate | 26 | $1,478 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Actelion Pharmaceuticals US, Inc.Opsumit | $99 | $444,00035 claims |
| GSKTrelegy Ellipta, Breo Ellipta, Anoro Ellipta | $692 | $422,714573 claims |
| Boehringer IngelheimOfev, Stiolto Respimat, Spiriva Respimat, Combivent Respimat | $216 | $395,833112 claims |
| Grifols USA, LLCProlastin C | $46 | $138,80112 claims |
| AstraZenecaBreztri Aerosphere, Symbicort | $205 | $47,645115 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 65th percentile of 189 pulmonary disease providers in Louisiana.
Other pulmonary disease in Covington
- Richard CaseyCovington$218K
- Rachele GibsonCovington$24K
- Ricardo BlancoCovington$17K
- David GreenShreveport$2M
- Joseph LaskyNew Orleans$1.9M
- Leonardo SeoaneNew Orleans$1.6M
- Ross KlingsbergNew Orleans$1.2M
- Juzar AliNew Orleans$775K
- Hollis O NealBaton Rouge$682K
- Andrea EspinozaHouma$655K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.